BioSpace News Archive

–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting– –Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints– –Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021–

Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger.

- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Tuesday, May 4, 2021 .

LabTrader, a provider of new and gently used brand-name, scientific equipment to universities, biotech and pharmaceutical companies, clinics, research laboratories and scientists around the country, recently received a huge shipment of scientific equipment for sale – low temperature freezers, biosafety cabinets, centrifuges, microscopes and more from premium brands such as Thermo Scientific, Ohaus, Olympus, and others.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the “Merger”) with CBPO Group Limited (“Merger Sub”), a wholly owned subsidiary of CBPO Holdings Limited (“Parent”

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday , May 5, 2021

Nuo Therapeutics, Inc. (OTC Pink: AURX) (“Nuo” or the “Company”), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021 , Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo

Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP), a severe dermatological disease with no specific approved treatments Phase III study in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is open for enrollment in the U.S. and Europe

Church & Dwight Canada Corp. is recalling certain lots of L’il Critters Gummy Vites children’s vitamins, as well as vitafusion Fibre Well and vitafusion MultiVites vitamins for adults, because certain lots may contain metal wire fragments.